Bayer Buys Perfuse for $2.45B, Eyeing Eye Care Revival

Bayers Acquisition of Perfuse Therapeutics: A Strategic Move for Ophthalmology Strength Bayer has agreed to acquire San Franciscos Perfuse Therapeutics for up to $2.45 billion, adding a promising eye treatment to their lineup. The deal includes an upfront payment of $300 million, with the rest tied to development, regulatory, and sales goals. The acquisition focuses on PER-021, a small molecule blocking endothelin receptors, currently in phase two trials for glaucoma and diabetic retinopathy. Bayer sees this as a potential game-changer, as it could be the first drug to modify these diseases rather than just manage symptoms. This move comes as Bayers blockbuster Eylea faces revenue pressure due to patent expiration and heart med Xarelto faces similar patent cliff pressure. The acquisition is Bayers biggest since snapping up AskBio for up to $4 billion in 2020 and signals a shift in their acquisition strategy, focusing on more mature assets. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/5b017c21e235e30f